Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trofinetide - ACADIA Pharmaceuticals/Neuren Pharmaceuticals

Next Previous
Drug Profile

Trofinetide - ACADIA Pharmaceuticals/Neuren Pharmaceuticals

Alternative Names: DAYBUE; G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; Glycyl-L-2-methylprolyl-L-glutamic acid; NNZ-2566

Latest Information Update: 07 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer ACADIA Pharmaceuticals; Neuren Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Anti-inflammatories; Glutamates; Neuropeptides; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Astrocyte inhibitors; Cytokine inhibitors; Glial cell inhibitors; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Rett syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Rett syndrome
  • Phase II Brain injuries; Fragile X syndrome; Traumatic brain injuries
  • Discontinued Autistic disorder; Multiple sclerosis

Most Recent Events

  • 31 Jan 2024 Acadia Pharmaceuticals plans a New Drug Submission (NDS) for Trofinetide in Canada in Q1 2024
  • 31 Jan 2024 Neuren Pharmaceuticals announces intention to engage with Japanese PMDA for Rett syndrome in 2024
  • 31 Jan 2024 Neuren Pharmaceuticals announces intention to submit MAA to EMA for Rett syndrome in H1 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top